Table 3.

Canonical summary of the sequenced circulating miRNAs in Senegalese sole females and males treated with kisspeptin hormone and control (untreated) during the different sampling points (2 d: 2-days and 4 d: 4-days post-injection). The raw reads, data after trimming (trimmed, trimmed data in percentage) and annotated microRNA reads and microRNA data in percentage are also indicated.

Kisspeptin treated	Sample ID	Sex	Sampling Point	Raw Reads	Trimmed	Trimmed %	microRNA	microRNA (%)
	A1-1_S1	Female	2 d	453,229	208,921	46	47,725	11
	A1-2_S2	Female	2 d	500,647	237,779	47	91,581	18
	A1-3_S3	Female	2 d	567,594	288,477	51	129,980	23
	A1-4_S4	Female	2 d	475,441	209,746	44	57,941	12
	A1-11-9_S5	Female	2 d	448,350	219,818	49	25,468	6
	A1-6_S11	Male	2 d	409,534	199,896	49	57,262	14
	A1-7_S12	Male	2 d	438,943	207,974	47	57,138	13
	A1-10_S13	Male	2 d	497,364	252,675	51	63,137	13
	A1-12_S14	Male	2 d	500,206	222,774	45	48,918	10
	A1-13_S15	Male	2 d	431,890	200,621	46	35,429	8
	A1-11-12_S16	Male	2 d	448,502	218,492	49	157,656	35
	A4-3_S26	Male	4 d	509,277	258,979	51	139,680	27
	A4-8_S27	Male	4 d	395,813	180,599	46	41,197	10
	A4-9_S28	Male	4 d	505,458	256,239	51	104,044	21
	A4-10_S29	Male	4 d	498,680	233,040	47	49,651	10
	A4-17_S30	Male	4 d	463,867	223,033	48	85,875	19
Control untreated	A2-2_S6	Female	2 d	461,160	227,736	49	191,846	42
	A2-5_S7	Female	2 d	491,359	243,485	50	163,635	33
	A2-7_S8	Female	2 d	415,844	192,516	46	124,752	30
	A2-9_S9	Female	2 d	475,556	211,070	44	84,252	18
	A2-10_S10	Female	2 d	443,098	218,571	49	52,960	12
	A2-11_S17	Male	2 d	496,908	245,995	50	39,267	8
	A2-12_S18	Male	2 d	488801	233,186	48	65,358	13
	A2-14_S19	Male	2 d	549,711	227,754	41	29,918	5
	A2-16_S20	Male	2 d	502,982	226,236	45	41,948	8
	A3-2_S21	Male	4 d	445,074	219,334	49	47,514	11
	A3-5_S22	Male	4 d	500,306	248,426	50	93,047	19
	A3-6_S23	Male	4 d	464,452	219,739	47	98,906	21
	A3-9_S24	Male	4 d	470,313	232,473	49	133,423	28
	A3-11_S25	Male	4 d	488,090	247,258	51	31,354	6